PLGA Acid Capped (PLGA-COOH, 75:25)

Price range: $120.00 through $720.00

PLGA Acid Capped (PLGA-COOH, 75:25) is a biodegradable poly(lactide-co-glycolide) copolymer with a 75:25 lactide ratio and a terminal carboxylic acid (COOH) group. The free carboxyl end group enables efficient bioconjugation and chemical modification, while the 75:25 composition provides an intermediate degradation rate suitable for sustained drug release. PLGA-COOH (75:25) is widely used in nanoparticle formulation, controlled drug delivery, tissue engineering, and biomaterials research.

Product Name: PLGA Acid Capped (PLGA-COOH, 75:25)
Alternative Name: Carboxyl-Terminated PLGA (75:25), PLGA-COOH (75:25)
Polymer Type: Poly(D,L-lactide-co-glycolide)
Lactide Ratio: 75:25
Molecular Weight: 2k, 5k, 10k, 15k, 20k, 30k, 50k, 100k Da, Custom
End Group: Carboxylic Acid (COOH)
Appearance: White to off-white powder or solid
Solubility: Dichloromethane, Chloroform, THF, Acetone, DMF, DMSO
Storage: -20°C, dry and protected from moisture
Purity: Typically ≥99%

 

Description

General Description

PLGA Acid Capped (75:25) is a carboxyl-terminated biodegradable polyester composed of 75% lactide and 25% glycolide. Compared with PLGA 50:50, the higher lactide content increases hydrophobicity and slows hydrolytic degradation, resulting in a longer drug release profile while maintaining excellent biodegradability and biocompatibility.

The terminal carboxylic acid group provides a versatile reactive handle for conjugation with polyethylene glycol (PEG), peptides, proteins, antibodies, fluorophores, targeting ligands, and other bioactive molecules using carbodiimide (EDC/NHS) coupling chemistry. Consequently, PLGA-COOH (75:25) is frequently used as a precursor for functional PLGA derivatives and targeted drug delivery systems.

PLGA Acid Capped (75:25) is widely employed in polymeric nanoparticles, microspheres, injectable depots, implantable drug delivery systems, tissue engineering scaffolds, and controlled-release formulations requiring moderate-to-long degradation times.

Applications

  • Controlled drug delivery
  • Sustained-release formulations
  • Nanoparticle formulation
  • Microsphere preparation
  • Injectable depot systems
  • PEG conjugation
  • Protein conjugation
  • Tissue engineering
  • Biomaterials development
  • Biomedical research

Features and Benefits

  • Terminal carboxylic acid functionality
  • 75:25 lactide composition
  • Intermediate degradation profile
  • Efficient EDC/NHS coupling
  • Excellent drug encapsulation capability
  • Excellent biocompatibility
  • Suitable for targeted polymer conjugates
  • Available in multiple molecular weights
  • Ideal precursor for PLGA derivatives

Additional information

Molecular weight

2K, 5K, 10K, 15K, 20K, 30K, 40K, 80K, 160K

Package size

1g, 5g, 10g